The UK Healthcare Agency (UKHSA) said on Friday that booster doses of the Kovit-19 vaccine provide significant protection against mild illnesses caused by the Ômicron variant, part of which is reversing a sharp drop in the effectiveness of vaccines.
The initial findings of an empirical study were part of the first data to protect against micronutrients from laboratory studies, which reduced the neutralizing activity of vaccines against micron.
“These initial assessments should be conducted with caution, but a few months after the second vaccination, there is a higher risk of Ômicron variant shrinkage compared to delta strain,” said Mary Ramsay, UKHSA’s head of immunization. It is believed that protection against serious diseases should be high.
“Data show that this risk is significantly reduced after booster vaccination, so I urge everyone to get their booster when they are eligible,” he added.
In an analysis of 581 people with confirmed micron, two doses of the AstraZeneca and Pfizer-BioNTech vaccines provided the lowest level of protection against symptomatic infections. Delta variant.
However, when the dose of Pfizer’s vaccine was increased, those who initially received the AstraZeneca vaccine had 70% protection against symptomatic infection and those who received the Pfizer had 75% protection.
In comparison, booster dose protection against delta variation is approximately 90%.
